NASDAQ: VOR
Vor Biopharma Inc.
Healthcare · Biotechnology
Per-share valuation inputs need verification
Event dated Mar 31, 2026Market-derived shares outstanding and recent statement shares differ materially. Per-share ratios and valuation outputs may be unreliable until the share base is verified. This sometimes appears with ADRs or provider share-count gaps.
Market Cap
$91.09M
52w High
$65.80
52w Low
$3.62
P/E
-0.01
Volume
868.20K
Outstanding Shares
6.85M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 197.98% over the last year. Free cash flow declined 49.74% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer.
Valuation
Stock splits
Every 20 shares became 1
Profitability & growth
Analyst consensus
10
Buy
3
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 11, 2026
Q3 FY26 · EPS est -$0.70 · Revenue est —
View